bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

SEATTLE--(BUSINESS WIRE)-- #shapelife--Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the appointment of Gary Fortin as Chief Operating Officer (COO). Prior to joining ShapeTX, Dr. Fortin was Head of Business Strategy and Operations for the Severe Genetic Disease unit of bluebird bio (NASDAQ:BLUE), where he navigated a portfolio of gene therapy programs through research, development, manufacturing, and co

Shape Therapeutics Announces Appointment of Gary Fortin as Chief Operating Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from Group C of its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin™ gene therapy (bb1111) for adult and adolescent patients with sickle cell disease (SCD) show a complete elimination of severe VOEs and VOEs between six and 24 months of follow-up. These data are being presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from Dece

Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events in Group C of Phase 1/2 HGB-206 Clinical Study Presented at 62nd Annual ASH Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today presented updated long-term efficacy and safety results reflecting up to six years of data for betibeglogene autotemcel gene therapy (beti-cel; formerly LentiGlobin™ for β-thalassemia) in patients with transfusion-dependent β-thalassemia (TDT). The company also presented results for pediatric patients in the Phase 3 HGB-207 (Northstar-2) and HGB-212 (Northstar-3) studies. These data were presented at the 62nd American So

Long-Term Data for bluebird bio's betibeglogene autotemcel (beti-cel) Gene Therapy Show Patients Across Ages and β-thalassemia Genotypes Achieve Transfusion Independence and Remain Free from Transfusions Up to Six Years Presented at 62nd ASH Meeting

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE #ASH2020--BMS and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020

Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?

Bluebird (BLUE) Down 3.8% Since Last Earnings Report: Can It Rebound?

Magenta Therapeutics Inc

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD). The data from this clinical trial could provide proof-of-concept for MGTA-145, in combination with plerixafor, as the preferred mobilization regimen for patien

Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta's MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease

It's a little-known company with lots going against it, but bluebird bio, Inc (NASDAQ:BLUE) has attracted investments from seven of the investing gurus followed by GuruFocus (and yes, the company's name is meant to be spelled without capital letters).

What's the Attraction of Bluebird Bio?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m. ET to review clinical data presented at the 62nd American Society of Hematology Annual Meeting and Exposition. Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conference ID number 3493595. To access the live webcast of blue

bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

Adaptive Biotechnologies

Blueprint Medicines

Novavax

Roche Holding AG

Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.

5 Under-the-Radar Tickers That Will Stomp the Market in 2021

Atlanta, Georgia--(Newsfile Corp. - November 11, 2020) - Holzer & Holzer, LLC is investigating whether bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) complied with federal securities laws. On November 4, 2020, the Company announced its submission to the FDA for approval of its bb1111 product will be delayed until late 2022. The price of bluebird's stock fell following the announcement. If you purchased shares of bluebird and suffered a loss on that...

SHAREHOLDER ALERT: Investigation of bluebird Announced by Holzer & Holzer, LLC

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: Cowen 2020 IO Next Summit, Friday, November 13, at 11:15 am ET Barclays Gene Editing & Gene Therapy Summit, Monday, November 16, at 7:45 am ET To access the live webcasts of bluebird bio's presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebi

bluebird bio Announces November Investor Events

Another manufacturing issue set the biotech's sickle cell disease program back much further than investors had hoped.

Can bluebird bio Recover From Another Major Setback?

A delay in submitting its sickle cell treatment to the FDA will push back a major source of future revenue.

Here's Why Bluebird's Shares Fell Out of the Nest Today

bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.

bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss

Shares of Bluebird bio Inc. traded 15.1% into the red in morning trading Thursday, after the gene therapy company pushed back the U.S. submission for approval of its sickle cell disease treatment LentiGlobin to late-2022 from the second half of 2021. The stock was headed toward the lowest close since April 15.

Bluebird bio's stock plunges after submission delay of sickle cell disease treatment

Bluebird Bio announced a delay for a gene therapy in treating sickle cell disease, leading BLUE stock to tumble early Thursday. Now, the company expects to ask for approval in late 2022.

Gene Therapy Stock Plunges On Unexpected Delay For Sickle Cell Drug

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that data from its gene and cell therapy programs for sickle cell disease (SCD), transfusion-dependent beta-thalassemia (TDT) and multiple myeloma (MM) will be presented, including seven oral presentations, at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from December 5-8, 2020. Updated results from patients in Group C of the company's Phase 1/2 HGB-206 stu

bluebird bio to Present Data from Gene and Cell Therapy Programs During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2020 and shared recent operational progress. “While 2020 continues to present unprecedented challenges, bluebird has continued to advance our innovative cell and gene therapy programs. Looking to 2021 and beyond, this is a catalyst-rich period for bluebird as we are on the cusp of multiple approvals in the U.S. and EU,” said Nick

bluebird bio Reports Third Quarter 2020 Financial Results and Highlights Operational Progress

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to bluebird bio Inc (NASDAQ:BLUE) changed recently.

Were These Hedge Funds Wrong About Buying bluebird bio Inc (BLUE)?

AbbVie

Amgen

Bristol-Myers

Mustang Bio

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.

7 Cutting-Edge Biotech Stocks for Tomorrow 

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Bluebird Bio (BLUE) Report Negative Q3 Earnings? What You Should Know

On Oct. 19, I reviewed three of the 10 companies a Jeffries health care analyst thinks are most likely to be acquired by members of Big Pharma. Now let's look at numbers four through six on the list Jeffries' Jaret Holtz provided to FierceBiotech.

Bristol-Myers' Acquisition of Bluebird Seems to Make Sense

Shares of bluebird bio Inc (NASDAQ: BLUE) are undervalued when weighed against the company's fundamentals, according to a Mizuho Securities analyst.  The Bluebird Bio Analyst: Difei Yang initiated coverage of Bluebird bio shares with a Buy rating and $123 price target.

Why This Bluebird Bio Analyst Sees Over 125% Upside Ahead

bluebird's (BLUE) MAA for elivaldogene autotemcel gene therapy for the treatment of patients with cerebral adrenoleukodystrophy is accepted by the the European Medicines Agency.

bluebird's MAA for Elivaldogene Autotemcel Accepted by EMA

Exact Sciences

The road ahead may be a bit rocky, but investing in these companies may pay off big-time -- eventually.

News for bluebird bio Stock (BLUE)